ArticleNeuromolecular medicine2026
PLAUR Exacerbates Neuroinflammation in Diabetic Ischemic Stroke by Driving Neutrophil-Mediated Blood-Brain Barrier Disruption and Reprogramming Microglial Metabolism.
Article in Neuromolecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic ischemic stroke leads to more severe brain damage. While the urokinase-type plasminogen activator receptor (PLAUR) is implicated in inflammation and cell migration, its precise role in diabetic stroke remains unclear. A streptozotocin-induced diabetic tMCAO mouse model was employed to simulate diabetic ischemic stroke. PLAUR expressions in mouse brain tissues were analyzed using microarray, Western blot, and immunofluorescence. PLAUR mRNA expression in endothelial cells (bEnd.3) was analyzed by RT-qPCR. We assessed cerebral infarct volume, brain water content, neurological deficits, and BBB integrity. Neutrophil infiltration (flow cytometry), inflammatory mediators, microglial polarization, and metabolic reprogramming (glycolytic proteins, ECAR/OCR) were investigated in vivo and in vitro. To test whether neutrophils are essential for PLAUR-mediated injury, we performed neutrophil depletion experiments using anti-Ly6G antibody, alone or combined with PLAUR knockdown. Neutrophil extracellular trap (NET) formation (CitH3 expression) and its impact on endothelial permeability and microglial polarization were also examined. PLAUR was significantly upregulated in the brains of diabetic stroke mice, particularly in microglia. PLAUR knockdown resulted in smaller infarct volumes, improved functional recovery, and maintained BBB integrity by restoring tight junction proteins. PLAUR knockdown was associated with reduced neutrophil infiltration, decreased pro-inflammatory mediator (MPO, MMP3) and attenuated pro-inflammatory M1 microglial polarization. PLAUR silencing also reduced NETosis in vivo and in isolated neutrophils. Neutrophil depletion alone significantly reduced infarct volume, improved neurological outcomes, and restored tight junction proteins; notably, PLAUR knockdown provided no additional benefit when neutrophils were already depleted, indicating that neutrophils are essential downstream effectors of PLAUR-mediated injury. Furthermore, PLAUR knockdown reversed the glycolytic shift in microglia. PLAUR is upregulated in diabetic ischemic stroke and its knockdown is associated with reduced neuroinflammation, preserved BBB integrity, decreased neutrophil infiltration, attenuated NETosis, and shifts in microglial polarization and metabolism. Therefore, targeting PLAUR represents a promising therapeutic strategy for attenuating brain injury in diabetic stroke.
Indexed as
Identifiers
42189433What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.